IRIS.TV
Total Consideration
$10.0M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.60% | 0.80% | -0.40% | 1.60% | -20.70% |
| Foreign Rate Differential | — | — | — | — | — |
| Other Adjustments | 0.00% | 0.90% | -2.10% | -0.70% | -1.80% |
| SBC (Nondeductible) | -3.20% | -2.90% | -12.50% | -7.20% | -0.30% |
| Valuation Allowance Change | -2.40% | -4.50% | 7.30% | 2.50% | -100.80% |
| Effective Tax Rate | 0.00% | 0.00% | -1.50% | 2.00% | -137.70% |
Cash vs Accrual
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | — | — | $151.0K | $249.0K | −$14.0M |
| Income Taxes Paid (Cash) | — | — | $305.0K | $161.0K | $412.0K |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$10.0M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).